




Anthralin

Revised: April 15, 2023.

CASRN: 1143-38-0



Drug Levels and Effects

Summary of Use during Lactation

Topical anthralin has not been studied during breastfeeding. Anthralin has suspected mutagenic properties, so it should only be used if the potential benefit to the mother justifies potential risk to the infant.[1] If anthralin is used, ensure that the infant's skin does not come into direct contact with the areas of maternal skin that have been treated and the infant does not ingest the product from the mother's skin.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. *Int J Womens Dermatol.* 2019;5:141–150. PubMed PMID: 31360745.

Substance Identification

Substance Name

Anthralin

CAS Registry Number

1143-38-0

Drug Class

Breast Feeding

Lactation

Milk, Human

Dermatologic Agents